Beat Cancer Foundation

Beat Cancer Foundation is a trusted resource for education on the metabolic approach to cancer, including the strategic use of non-toxic, repurposed drugs such as Fenbendazole, Ivermectin, and others—used as part of an integrative, individualized strategy.

They’re a Telehealth nonprofit that guides, supports and empowers you at every step of your journey for over six years now. They attack cancer from 9 different angles helping people beat cancer. 🙏🏼

A new peer-reviewed paper is drawing attention in the world of cancer research by exploring whether existing, low-cost drugs could potentially play a role in future cancer therapies. It comes from one of the world’s highly credentialed and accomplished critical care physicians, Dr. Paul Marik.

Published in the Journal of Orthomolecular Medicine, the paper, titled “Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol,” was authored by researchers including Ilyes Baghli, Pierrick Martinez, Dr. Paul Marik, and other collaborators.

The paper examines a combination approach involving repurposed medications such as ivermectin, mebendazole, and fenbendazole, alongside nutritional and metabolic strategies. The authors explore the idea that targeting cancer metabolism, mitochondrial function, inflammation, and cancer stem cell pathways may offer new avenues for treatment.

Instead of developing entirely new medicines from scratch, researchers are investigating whether existing medications, already known in other medical contexts, may have overlooked anti-cancer properties.

The next important step would be rigorous human studies to determine whether these approaches actually improve outcomes for patients.

The future of cancer care will depend not only on discovering new treatments, but also on having the curiosity and scientific rigor to explore unconventional possibilities while following the evidence. Sadly, the pharmaceutical industry may frown upon such methods because they are cheap and highly accessible.